Phase I trial of Bevacizumab and S-1 chemotherapy for patients with previously treated advanced non-small cell lung cancer - Bevacizumab and S-1 for previously treated advanced non-small cell lung cancer

Thoracic Medical Oncology Cancer Institute Hospital of Japanese Foundation for Cancer Research0 个研究点目标入组 15 人开始时间: 2012年8月6日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1)Interstitial pneumonia or pulmonary fibrosis detectable on X ray. 2)Patients with uncontrollable complications(e.g. uncontrollable heart disease, severe arrhythmia, continuous diarrhea). 3)Patients with active severe infections. 4)History of active double cancer within 5 years prior to the study. 6)Patients with symptomatic brain metastasis 7) 8)History of hemoptysis with 2.5mL or more and Continued bloody phlegm. 9)Pregnancy or lactation 10)evidence of bleeding diathesis or coagulopathy 11)tumor invasive to the chest large blood vessel. Cavity in brain or lung tumor 12)current or previous (within the last 1 year) history of GI perforation 13)current history of uncontrorable hypertension 14)Impossible cases with oral administration. 15)severe drug allergy for 5-FU or UFT or S-1 content medicine 16) Any other medical condition that makes the patient unsuitable for inclusion in the study according to the opinion of the investigator.

发起方

Thoracic Medical Oncology Cancer Institute Hospital of Japanese Foundation for Cancer Research